BR112021020605A2 - Inibidor de mek para o tratamento de infecções virais e bacterianas - Google Patents
Inibidor de mek para o tratamento de infecções virais e bacterianasInfo
- Publication number
- BR112021020605A2 BR112021020605A2 BR112021020605A BR112021020605A BR112021020605A2 BR 112021020605 A2 BR112021020605 A2 BR 112021020605A2 BR 112021020605 A BR112021020605 A BR 112021020605A BR 112021020605 A BR112021020605 A BR 112021020605A BR 112021020605 A2 BR112021020605 A2 BR 112021020605A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral
- treatment
- mek inhibitor
- bacterial infections
- infection
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 4
- 230000003612 virological effect Effects 0.000 title abstract 3
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 229940124647 MEK inhibitor Drugs 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 208000003322 Coinfection Diseases 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU101183A LU101183B1 (en) | 2019-04-16 | 2019-04-16 | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| PCT/EP2020/060692 WO2020212478A1 (en) | 2019-04-16 | 2020-04-16 | Novel mek-inhibitor for the treatment of viral and bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020605A2 true BR112021020605A2 (pt) | 2021-12-07 |
Family
ID=66554457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020605A BR112021020605A2 (pt) | 2019-04-16 | 2020-04-16 | Inibidor de mek para o tratamento de infecções virais e bacterianas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12350244B2 (https=) |
| EP (1) | EP3955908B1 (https=) |
| JP (2) | JP2022529343A (https=) |
| KR (1) | KR20210153642A (https=) |
| CN (1) | CN114007598A (https=) |
| AU (1) | AU2020258002B2 (https=) |
| BR (1) | BR112021020605A2 (https=) |
| CA (1) | CA3136171A1 (https=) |
| EA (1) | EA202192454A1 (https=) |
| ES (1) | ES3012533T3 (https=) |
| LU (1) | LU101183B1 (https=) |
| MX (1) | MX2021012604A (https=) |
| WO (1) | WO2020212478A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3912623B1 (en) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| EP4186500A1 (en) * | 2021-11-24 | 2023-05-31 | Atriva Therapeutics GmbH | Mek inhibitors for the prevention and treatment of long covid syndrome |
| WO2024042050A1 (en) * | 2022-08-22 | 2024-02-29 | Atriva Therapeutics Gmbh | Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs |
| CN119931962B (zh) * | 2025-04-07 | 2025-08-05 | 北京华诺泰生物医药科技有限公司 | 一种人偏肺病毒的培养方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000040237A1 (en) * | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| KR20020012315A (ko) * | 1999-07-16 | 2002-02-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 |
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| WO2014056894A1 (en) | 2012-10-08 | 2014-04-17 | Westfaelische Wilhelms-Universitaet Muenster | Mek inhibitors in the treatment of virus diseases |
| CN113398271A (zh) | 2014-05-16 | 2021-09-17 | 归属疗法有限公司 | 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略 |
| EP3973960B1 (en) * | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| KR20220074869A (ko) * | 2019-08-27 | 2022-06-03 | 아트리바 테라퓨틱스 게엠베하 | Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합 |
| JP7802365B2 (ja) * | 2019-10-08 | 2026-01-20 | アトリバ セラピューティクス ゲーエムベーハー | ハンタウイルス感染症の処置のためのｍｅｋ阻害剤 |
| EP3912623B1 (en) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
-
2019
- 2019-04-16 LU LU101183A patent/LU101183B1/en active IP Right Grant
-
2020
- 2020-04-16 ES ES20724748T patent/ES3012533T3/es active Active
- 2020-04-16 WO PCT/EP2020/060692 patent/WO2020212478A1/en not_active Ceased
- 2020-04-16 AU AU2020258002A patent/AU2020258002B2/en active Active
- 2020-04-16 MX MX2021012604A patent/MX2021012604A/es unknown
- 2020-04-16 JP JP2021561625A patent/JP2022529343A/ja active Pending
- 2020-04-16 EA EA202192454A patent/EA202192454A1/ru unknown
- 2020-04-16 EP EP20724748.7A patent/EP3955908B1/en active Active
- 2020-04-16 CA CA3136171A patent/CA3136171A1/en active Pending
- 2020-04-16 BR BR112021020605A patent/BR112021020605A2/pt not_active Application Discontinuation
- 2020-04-16 US US17/604,355 patent/US12350244B2/en active Active
- 2020-04-16 CN CN202080044394.4A patent/CN114007598A/zh active Pending
- 2020-04-16 KR KR1020217036169A patent/KR20210153642A/ko active Pending
-
2025
- 2025-05-19 JP JP2025083321A patent/JP2025124703A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025124703A (ja) | 2025-08-26 |
| KR20210153642A (ko) | 2021-12-17 |
| EA202192454A1 (ru) | 2022-03-22 |
| JP2022529343A (ja) | 2022-06-21 |
| LU101183B1 (en) | 2020-10-16 |
| CA3136171A1 (en) | 2020-10-22 |
| CN114007598A (zh) | 2022-02-01 |
| US20220193017A1 (en) | 2022-06-23 |
| AU2020258002B2 (en) | 2025-12-18 |
| AU2020258002A1 (en) | 2021-11-18 |
| ES3012533T3 (en) | 2025-04-09 |
| EP3955908A1 (en) | 2022-02-23 |
| MX2021012604A (es) | 2021-11-12 |
| US12350244B2 (en) | 2025-07-08 |
| WO2020212478A1 (en) | 2020-10-22 |
| EP3955908C0 (en) | 2025-01-22 |
| EP3955908B1 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023013A2 (pt) | Inibidores de mek para tratamento ou prevenção de infecções por coronavírus e/ou de tempestade de citocinas de covid-19 | |
| MX2022016066A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| BR112021020605A2 (pt) | Inibidor de mek para o tratamento de infecções virais e bacterianas | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| BR112022005896A2 (pt) | Inibidores da mek para o tratamento de infecções causadas por hantavírus | |
| BR112016026556A8 (pt) | inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção | |
| WO2009111064A3 (en) | Minocycline compounds and methods of use thereof | |
| BR112023021422A2 (pt) | Partículas interferentes terapêuticas para corona vírus | |
| MX2025002439A (es) | Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv | |
| BR112022001341A2 (pt) | Inibidores de enzima | |
| BR112022000041A2 (pt) | Inibidores de detecção de quorum e / ou metabólitos pósbióticos e métodos relacionados | |
| BR112022001054A2 (pt) | Inibidores enzimáticos | |
| WO2021158635A8 (en) | Anti-viral compositions and methods of use | |
| BR112022001390A2 (pt) | Inibidores de enzima | |
| BR112022001025A2 (pt) | Inibidores de calicreína plasmática | |
| EP4213820A4 (en) | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS | |
| EP4436667C0 (en) | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| MX2017012535A (es) | Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| EP4508077A4 (en) | COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS | |
| BR112017028190A2 (pt) | Peptídeo, peptídeo peguilado, composição, composição farmacêutica, frasco, solução de desinfecção, método para inibição de crescimento, replicação ou infectividade de um micro- organismo, método para inibição de crescimento bacteriano, método para inibição de replicação viral em uma célula, método para tratamento de uma infecção de micro-organismo em um sujeito e prevenção de uma doença em um sujeito causada por ou associada a uma infecção de micro- organismo, método para inibição de crescimento bacteriano em um sujeito, método para tratamento de uma infecção bacteriana em um sujeito e tratamento de uma doença causada por ou associada a uma infecção bacteriana, método para prevenção de uma doença causada por ou associada a uma infecção bacteriana em um sujeito, método para inibição de replicação viral em um sujeito, método para tratamento de uma infecção viral em um sujeito e tratamento de uma doença causada por ou associada a uma infecção viral em um sujeito, método para prevenção de uma doença causada por ou associada a uma infecção viral em um sujeito, método para desinfecção de um objeto inanimado ou material biológico e superfície inanimada ou superfície biológica | |
| BR112021022902A2 (pt) | Métodos e composições que compreendem variantes de proteína a staphylococcus (spa) | |
| EP4125893A4 (en) | TECHNOLOGIES FOR PREVENTION OR TREATMENT OF INFECTIONS | |
| MX2017012539A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| BR112022019685A2 (pt) | Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus | |
| BR112021022270A2 (pt) | Materiais e métodos para tratar degeneração macular relacionada à idade |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |